



# MyCLL

## PATIENT SUPPORT PROGRAMME

**Helping your patients to manage the emotional and psychosocial challenges of chronic lymphocytic leukaemia (CLL)**

Please note, the support offered to patients within the MyCLL programme will under no circumstances interfere with the relationships that patients have with their healthcare team. The objective of the programme is to predominantly offer emotional and psychosocial support to complement your professional guidance.

This material is for UK healthcare professionals only. MyCLL is a patient support programme initiated, managed and fully funded by AstraZeneca UK. MyCLL is intended for UK patients that have been prescribed Calquence®▼ (acalabrutinib).

Adverse events should be reported. Reporting forms and information can be found at <http://yellowcard.mhra.gov.uk/> or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting <https://contactazmedical.astrazeneca.com> or by calling 0800 783 0033.

Prescribing information can be found on the inside back cover of this leaflet.  
Images throughout are stock images, not real patients.

AstraZeneca 

GB-63659  
Date of Preparation: January 2025

# WHAT IS *My*CLL?

---

MyCLL is a personalised,  
self-management  
programme to  
support adult  
patients prescribed  
Calquence® ▼  
(acalabrutinib) for CLL



**MyCLL is designed to work in partnership with you and your team, and aims to support patients with the emotional and psychosocial impact that managing CLL can have on daily life.<sup>1</sup>**

MyCLL delivers services intended to help:

- Improve patient understanding of CLL
- Support patients with the emotional challenges of a CLL diagnosis
- Patients improve their day to day life by supporting their psychosocial challenges
- Patients engage in the most beneficial way with your team

The programme is based on research that shows that tailored patient education can help ease the concerns of cancer patients and complement the care offered by healthcare service providers.<sup>2,3</sup>

*“MyCLL is underpinned by an in-depth understanding of patient needs. Patients on this programme receive a number of personalised interventions, designed to support them to make the necessary lifestyle changes to help them live with CLL and to take their prescribed medication correctly.”*

- Professor John Weinman, Professor of Psychology as applied to Medicines in the School of Cancer & Pharmaceutical Sciences, King's College London\*


\*Professor John Weinman is affiliated with Atlantis Health, which has been responsible for the development of the MyCLL programme on behalf of AstraZeneca.




# HOW *my*CLL CAN HELP YOUR PATIENTS

MyCLL patient resources can be personalised following an optional belief-based questionnaire conducted at programme initiation.

The multi-channel resource offers support to complement and reinforce the advice patients receive from you and your team.



ID-7587 | WPM ID: GB-37334 | Date of Prep: July 2022



ID-7587 | GB-28683 | Date of Preparation: August 2021

Online and printed tools address disease awareness and CLL management concerns, while additional tools – such as text message medication reminders – recognise the challenges of self-management and support treatment adherence.

If your patient opts in, you will be provided with regular feedback about each patient's progress on the programme. You will be able to opt out of email communications if preferred.

# WHAT EXACTLY DO PATIENTS RECEIVE FROM *My*CLL?

---



## Online advice

MyCLL.co.uk is a personalised patient website with information and interactive support on various aspects of living with CLL, including:

- Advice on living well with CLL, including nutrition and exercise
- Advice for managing emotional wellbeing
- Day to day life management and goal-setting support
- Information to encourage positive patient-healthcare team dialogue
- A CLL symptom tracker



## Community support videos

- Guidance and advice from nurses on managing psychosocial challenges
- Patient story videos to share experiences



## SMS and email services

- Medication reminders
- Belief-based SMS
- Communications to encourage programme engagement



## Healthcare provider access

- Emails summarising each patient's MyCLL progress, if your patient has consented
- Overview programme webpage

#### References:

1. Westbrook TD, Morrison EJ, Maddocks KJ, *et al.* Illness Perceptions in Chronic Lymphocytic Leukemia: Testing Leventhal's Self-regulatory Model. *Ann Behav Med.* 2019;53(9):839-848. doi:10.1093/abm/kay093.
2. Wood LS, Moldawer NP, Lewis C. Immune Checkpoint Inhibitor Therapy: Key Principles When Educating Patients. *Clin J Oncol Nurs.* 2019;23(3):271-280. doi:10.1188/19.CJON.271-280.
3. Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. *CA Cancer J Clin.* 2009;59(1):56-66. doi:10.3322/caac.20004.

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. More information about Calquence® (acalabrutinib) can be found in the Summary of Product Characteristics.

[Click here](#) or scan the  
QR code to view the UK  
prescribing information



Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard) or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting <https://contactazmedical.astrazeneca.com> or by calling 0800 783 0033.

# HOW TO HELP YOUR PATIENTS ENROL

The enrolment is a straightforward and quick online process. Patients go through a simple three-step process to input their details, confirm their eligibility and communication preferences, and review the consent statements before being given access to MyCLL.

For some patients, you may wish to walk through the enrolment process with them during your consultation by following one of the three steps below.

**There are three easy ways for patients to sign up at home:**



**Visit [www.MyCLL.co.uk](http://www.MyCLL.co.uk)**



**Text ENROL to 07937 947821 to receive an enrolment link by SMS**



**Scan the QR code with their mobile phone**



Please include your email address in the available space on the patient introduction kit before distributing it. Patients will need to enter your contact details at enrolment in order for you to receive the PSP feedback.

If you have any questions about MyCLL, please speak to your local AstraZeneca representative or email [MyCLL\\_support@atlantishealthcare.com](mailto:MyCLL_support@atlantishealthcare.com)